0001193125-24-170510.txt : 20240627 0001193125-24-170510.hdr.sgml : 20240627 20240627160548 ACCESSION NUMBER: 0001193125-24-170510 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240627 FILED AS OF DATE: 20240627 DATE AS OF CHANGE: 20240627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Achilles Therapeutics plc CENTRAL INDEX KEY: 0001830749 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40299 FILM NUMBER: 241079169 BUSINESS ADDRESS: STREET 1: 245 HAMMERSMITH ROAD CITY: LONDON STATE: X0 ZIP: W6 8PW BUSINESS PHONE: 44 (0)20 8154 4600 MAIL ADDRESS: STREET 1: 245 HAMMERSMITH ROAD CITY: LONDON STATE: X0 ZIP: W6 8PW FORMER COMPANY: FORMER CONFORMED NAME: Achilles Therapeutics Ltd DATE OF NAME CHANGE: 20201030 6-K 1 d835850d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of June 2024

Commission File Number: 001-40299

 

 

Achilles Therapeutics plc

(Exact name of registrant as specified in its charter)

 

 

245 Hammersmith Road

London W6 8PW

United Kingdom

Tel: +44 (0)20 8154 4600

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

 

 

 

Results of Annual General Meeting

On June 25, 2024, Achilles Therapeutics plc (“Achilles” or the “Company”) held its 2024 Annual General Meeting (the “Annual General Meeting”), and all resolutions were passed as proposed. At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting sent to shareholders on May 24, 2024 were duly proposed and passed on a poll.

The matters presented for a vote and the related results are as follows:

 

Ordinary Resolutions    For      Against      Abstain  

To re-elect Edwin Moses as a Director of the Company.

      6,756,604        190,295        11,167,811  

To re-elect Iraj Ali as a Director of the Company.

      6,798,071        150,222        11,166,417  

To re-elect Carsten Boess as a Director of the Company.

      6,803,027        143,394        11,168,289  

To re-elect Bernhard Ehmer as a Director of the Company.

      6,808,607        137,814        11,168,289  

To re-elect Michael Giordano as a Director of the Company.

      6,720,495        142,294        11,251,921  

To re-elect Julie O’Neill as a Director of the Company.

      6,796,562        149,859        11,168,289  

To re-appoint KPMG LLP as UK statutory auditors of the Company, to hold office until the conclusion of the next Annual General Meeting.

      6,898,359        27,858        11,188,493  

To authorize the Company’s Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2024.

      6,888,016        58,323        11,168,371  

To receive the UK statutory annual accounts and report for the fiscal year ended 31 December 2023 and to note that the Directors do not recommend the payment of any dividend for the year ended December 31, 2023.

      6,882,217        56,252        11,176,241  

To receive and approve, on a non-binding, advisory basis, the Company’s UK statutory Directors’ Remuneration Report for the year ended December 31, 2023.

      4,513,763        2,423,898        11,177,049  

The full text of each resolution passed at the Annual General Meeting is set out in the Notice of Annual General Meeting sent to shareholders on May 24, 2024 and furnished as an exhibit to a Form 6-K filed with the U.S. Securities and Exchange Commission on May 24, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ACHILLES THERAPEUTICS PLC
Date: June 27, 2024     By:  

/s/ Robert Coutts

      Robert Coutts
      Chief Financial Officer